Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$88.0KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- David Hochman
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 86
- Beta
- 0.53
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -2.80
Financials
Revenue
$88.0K-93.3%Net Income
$-23.75MEBITDA
$-23.66MFree Cash Flow
$-19.59MEPS (diluted)
$-0.38Shares Outstanding (diluted)
63.81M+212.0%Operating Expenses
$22.42MCash & Debt
$109.96MReturn of Capital
$616.0KRevenue by Segment (annual)
$611.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $33.48M | $-52.70M | $-1.11 |
| 2024 | $2.64M | $-61.02M | $-1.66 |
| 2023 | $2.76M | $-49.12M | $-1.48 |
| 2022 | $3.53M | $-33.61M | $-1.32 |
| 2021 | $-782.0K | $-23.01M | $-0.02 |
| 2020 | $5.70M | $-21.36M | $-0.01 |
Valuation
OBIOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (3)
- Newszacks.com·15d ago·Neutral
Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength? Orchestra BioMed Holdings, Inc. (OBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
View source ↗ - Newsglobenewswire.com·20d ago·Negative
…Med Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026 NEW HOPE, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced that its investigational Atrioventricular Interval Modulation Therapy ("AVIM Therapy") will be featured in two session…
View source ↗ - Newsglobenewswire.com·47d ago·Neutral
… BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference NEW HOPE, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that Chairman and CEO David Hochman will present at the Wells Fargo 21st Annual Healthcare Conference on Thursday, Sept. 10, 2026 at 1:30pm ET and will also host…
View source ↗
Earnings
Mon, Nov 9(in 5 weeks)
Consensus estimate $-0.40 per share
Typical surprise +3.1% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.38 vs $-0.39beat
- Tue, May 12$-0.33 vs $-0.40beat
- Thu, Mar 12$0.12 vs $-0.38beat
- Mon, Nov 10$-0.40 vs $-0.38miss
- Tue, Aug 12$-0.50 vs $-0.51beat
- Wed, Apr 2$-0.43 vs $-0.43beat
Estimates and results for OBIO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by OBIO officers and directors.
- Bought
- $2.3m
- Sold
- $361k
18 trades
7 trades
- Sherman Darrensold
- Hochman David Pbought
- Sherman Darrensold
- Sherman Darrenbought
- Sherman Darrensold
- Sherman Darrensold
- Hochman David Pbought
- Sherman Darrensold
75 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in OBIO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.